首页> 美国卫生研究院文献>Frontiers in Immunology >Maternal Antibodies: Clinical Significance Mechanism of Interference with Immune Responses and Possible Vaccination Strategies
【2h】

Maternal Antibodies: Clinical Significance Mechanism of Interference with Immune Responses and Possible Vaccination Strategies

机译:孕产妇抗体:临床意义免疫反应的干扰机制和可能的疫苗接种策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Neonates have an immature immune system, which cannot adequately protect against infectious diseases. Early in life, immune protection is accomplished by maternal antibodies transferred from mother to offspring. However, decaying maternal antibodies inhibit vaccination as is exemplified by the inhibition of seroconversion after measles vaccination. This phenomenon has been described in both human and veterinary medicine and is independent of the type of vaccine being used. This review will discuss the use of animal models for vaccine research. I will review clinical solutions for inhibition of vaccination by maternal antibodies, and the testing and development of potentially effective vaccines. These are based on new mechanistic insight about the inhibitory mechanism of maternal antibodies. Maternal antibodies inhibit the generation of antibodies whereas the T cell response is usually unaffected. B cell inhibition is mediated through a cross-link between B cell receptor (BCR) with the Fcγ-receptor IIB by a vaccine–antibody complex. In animal experiments, this inhibition can be partially overcome by injection of a vaccine-specific monoclonal IgM antibody. IgM stimulates the B cell directly through cross-linking the BCR via complement protein C3d and antigen to the complement receptor 2 (CR2) signaling complex. In addition, it was shown that interferon alpha binds to the CD21 chain of CR2 as well as the interferon receptor and that this dual receptor usage drives B cell responses in the presence of maternal antibodies. In lieu of immunizing the infant, the concept of maternal immunization as a strategy to protect neonates has been proposed. This approach would still not solve the question of how to immunize in the presence of maternal antibodies but would defer the time of infection to an age where infection might not have such a detrimental outcome as in neonates. I will review successful examples and potential challenges of implementing this concept.
机译:新生儿的免疫系统不成熟,无法充分预防传染病。在生命的早期,免疫保护是通过将母体抗体从母亲转移到后代来实现的。但是,降解的母源抗体会抑制疫苗接种,例如麻疹疫苗接种后血清转化的抑制就是例证。在人类和兽医学中都已经描述了这种现象,并且与所使用的疫苗类型无关。本文将讨论动物模型在疫苗研究中的应用。我将回顾通过母源抗体抑制疫苗接种的临床解决方案,以及潜在有效疫苗的测试和开发。这些是基于有关母体抗体抑制机制的新机制的见解。母体抗体抑制抗体的产生,而T细胞反应通常不受影响。疫苗抗体复合物通过B细胞受体(BCR)与Fcγ受体IIB之间的交联来介导B细胞抑制作用。在动物实验中,可以通过注射疫苗特异性单克隆IgM抗体部分克服这种抑制作用。 IgM通过补体蛋白C3d和抗原将BCR交联到补体受体2(CR2)信号复合体上直接刺激B细胞。另外,已表明干扰素α与CR2的CD21链以及干扰素受体结合,并且这种双重受体的使用在母体抗体存在下驱动B细胞应答。代替免疫婴儿,已经提出了将母体免疫作为保护新生儿的策略的概念。这种方法仍不能解决在存在母源抗体的情况下如何进行免疫的问题,但会将感染时间推迟到感染可能不会像新生儿那样有害的年龄。我将回顾成功的例子以及实施该概念的潜在挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号